LobbyingPacira Pharmaceuticals lobbying by quarter
Pacira Pharmaceuticals's latest lobbying report covers Q2 2026, at $90K. The four quarters Q3 2025–Q2 2026 total $300K. Its first report covers Q1 2020; the issues it reports most are Health Issues.
Pacira Pharmaceuticals
- Latest quarter
- $90K
- Q2 2026 · 1 reports
- Last 12 months
- $300K
- Last 4 quarters
- vs last quarter
- 0.0%
- Q2 2026 against the quarter before
- First report
- Q1 2020
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2020 | $190K | 1 |
| Q2 2020 | $0 | 0 |
| Q3 2020 | $0 | 0 |
| Q4 2020 | $0 | 0 |
| Q1 2021 | $0 | 0 |
| Q2 2021 | $0 | 0 |
| Q3 2021 | $0 | 0 |
| Q4 2021 | $0 | 0 |
| Q1 2022 | $0 | 0 |
| Q2 2022 | $0 | 0 |
| Q3 2022 | $0 | 0 |
| Q4 2022 | $110K | 1 |
| Q1 2023 | $120K | 1 |
| Q2 2023 | $110K | 1 |
| Q3 2023 | $110K | 1 |
| Q4 2023 | $110K | 1 |
| Q1 2024 | $90K | 1 |
| Q2 2024 | $50K | 1 |
| Q3 2024 | $90K | 1 |
| Q4 2024 | $70K | 1 |
| Q1 2025 | $60K | 1 |
| Q2 2025 | $60K | 1 |
| Q3 2025 | $60K | 1 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $90K | 1 |
| Q2 2026 | $90K | 1 |
Policy issues the reports name
- Health issues16 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES16 reports
- SENATE16 reports
- Health & Human Services, Dept of (HHS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Venn Strategies | $1.5M | 16 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Venn Strategies | $90K |
| 07/02for Q1 2020 | Venn Strategies | $190K |
| 04/15for Q1 | Venn Strategies | $90K |
| 01/20for Q4 2025 | Venn Strategies | $60K |
| 25/10/20for Q3 2025 | Venn Strategies | $60K |
| 25/07/18for Q2 2025 | Venn Strategies | $60K |
| 25/04/21for Q1 2025 | Venn Strategies | $60K |
| 25/01/21for Q4 2024 | Venn Strategies | $70K |
| 24/10/16for Q3 2024 | Venn Strategies | $90K |
| 24/07/22for Q2 2024 | Venn Strategies | $50K |
| 24/04/19for Q1 2024 | Venn Strategies | $90K |
| 24/01/19for Q4 2023 | Venn Strategies | $110K |
| 23/10/20for Q3 2023 | Venn Strategies | $110K |
| 23/07/20for Q2 2023 | Venn Strategies | $110K |
| 23/04/18for Q1 2023 | Venn Strategies | $120K |
| 23/01/20for Q4 2022 | Venn Strategies | $110K |